These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8960292)

  • 1. Synthesis and activity of N epsilon-aminocaproyl-L-norleucine derivatives.
    Midura-Nowaczek K; Bruzgo I; Roszkowska-Jakimiec W; Worowski K
    Acta Pol Pharm; 1996; 53(3):221-3. PubMed ID: 8960292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and activity of dipeptides containing epsilon-aminocaproic acid.
    Midura-Nowaczek K; Bruzgo I; Roszkowska-Jakimiec W; Worowski K
    Acta Pol Pharm; 1994; 51(6):499-504. PubMed ID: 7762400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of epsilon-aminocaproylamino acids on fibrin formation.
    Bruzgo I; Midura-Nowaczek K; Bruzgo M; Kaczyńska J; Roszkowska-Jakimiec W
    Acta Pol Pharm; 2006; 63(2):149-52. PubMed ID: 17514879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of some epsilon-aminocaproic acid derivatives on platelet responses.
    Bruzgo I; Tomasiak M; Stelmach H; Midura-Nowaczek K
    Acta Biochim Pol; 2004; 51(1):73-80. PubMed ID: 15094827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrinolytic activity of epsilon-aminocaproyl derivatives of amino acids.
    Midura-Nowaczek K; Bruzgo I; Dubis E; Roszkowska-Jakimiec W; Worowski K
    Pharmazie; 1996 Oct; 51(10):775-7. PubMed ID: 8941949
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of epsilon-aminocaproiloaminoacids on the amidolytic activity of tissue plasminogen activator, urokinase and kallikrein.
    Midura-Nowaczek K; Bruzgo I; Roszkowska-Jakimiec W; Markowska A
    Acta Pol Pharm; 2004; 61(1):75-6. PubMed ID: 15259861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of epsilon-aminocaproyl-S-benzyl-L-cysteine on the activity of plasminogen activators.
    Bruzgo I; Midura-Nowaczek K; Kaczyńska J; Krajewska D
    Acta Pol Pharm; 2009; 66(1):37-40. PubMed ID: 19226966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the mechanism of action of synthetic antifibrinolytics. A comparison with the action of derivatives of benzamidine on the fibrinolytic process.
    Landmann H
    Thromb Diath Haemorrh; 1973 May; 29(2):253-75. PubMed ID: 4271586
    [No Abstract]   [Full Text] [Related]  

  • 9. Short peptides containing L-lysine and epsilon-aminocaproic acid as potential plasmin inhibitors.
    Purwin M; Bruzgo I; Markowska A; Midura-Nowaczek K
    Pharmazie; 2009 Nov; 64(11):765-7. PubMed ID: 20099524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new strategy for the development of highly potent and selective plasmin inhibitors.
    Saupe SM; Steinmetzer T
    J Med Chem; 2012 Feb; 55(3):1171-80. PubMed ID: 22276953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of short peptides containing lysine and epsilon-aminocaproic acid on fibrinolytic activity of plasmin and topoisomerase II action on supercoiled DNA.
    Midura-Nowaczek K; Purwin M; Markowska A; Drozdowska D; Bruzgo M
    Acta Pol Pharm; 2013; 70(3):431-4. PubMed ID: 23757933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.
    Teno N; Gohda K; Wanaka K; Tsuda Y; Sueda T; Yamashita Y; Otsubo T
    Bioorg Med Chem; 2014 Apr; 22(7):2339-52. PubMed ID: 24613052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin.
    Xue F; Seto CT
    J Org Chem; 2005 Oct; 70(21):8309-21. PubMed ID: 16209572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basis of antifibrinolytic therapy.
    Prentice CR
    J Clin Pathol Suppl (R Coll Pathol); 1980; 14():35-40. PubMed ID: 6159375
    [No Abstract]   [Full Text] [Related]  

  • 15. [Synthesis and properties of antifibrinolytic dipeptides containing E-aminocaproic acid].
    Midura-Nowaczek K; Bruzgo I; Popławski J; Roszkowska-Jakimiec W; Worowski K
    Acta Pol Pharm; 1992; 49(1-2):89-92. PubMed ID: 8769082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of epsilon-aminocaproylaminoacids on the activity of proteolytic enzymes.
    Bruzgo I; Midura-Nowaczek K; Roszkowska-Jakimiec W; Jasielczuk J
    Acta Pol Pharm; 2001; 58(2):137-40. PubMed ID: 11501792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of epsilon-aminocaproylaminoacids on fibrinolytic and caseinolytic activity of euglobulin fraction.
    Midura-Nowaczek K; Bruzgo I; Popławski J; Roszkowska-Jakimiec W; Worowski K
    Acta Pol Pharm; 1998; 55(2):159-61. PubMed ID: 9673155
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimization of Cyclic Plasmin Inhibitors: From Benzamidines to Benzylamines.
    Hinkes S; Wuttke A; Saupe SM; Ivanova T; Wagner S; Knörlein A; Heine A; Klebe G; Steinmetzer T
    J Med Chem; 2016 Jul; 59(13):6370-86. PubMed ID: 27280436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of fibrinolytic activity after epsilon-aminocaproic acid administration in rats (Rattus norvegicus).
    Gogjian MA; Barry KJ; Stein BM
    Lab Anim Sci; 1981 Dec; 31(6):710-1. PubMed ID: 7343767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and activity of N alpha-(epsilon-aminocaproyl)-alanines and N epsilon-(epsilon-aminocaproyl)-caproic acid.
    Midura-Nowaczek K; Bruzgo I; Popławski J; Roszkowska-Jakimiec W; Worowski K
    Acta Pol Pharm; 1995; 52(6):505-7. PubMed ID: 8960269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.